Expression cassettes containing the codons for the pestivirus E rns signal peptide (Sig) followed by a chemically synthesized ORF that encoded the bovine viral diarrhoea virus (BVDV) strain C86 glycoprotein E2, a class I membrane glycoprotein, were constructed with and without a chimeric intron sequence immediately upstream of the translation start codon, and incorporated into the genome of bovine herpesvirus-1 (BHV-1). The resulting recombinants, BHV-1/SigE2 syn and BHV-1/SigE2 syn -intron, expressed comparable quantities of glycoprotein E2, and Northern blot hybridizations indicated that the presence of the intron did not increase significantly the steadystate levels of transcripts encompassing the SigE2 syn ORF. In BHV-1/SigE2 syn -infected cells, the 54 kDa E2 glycoprotein formed a dimer with an apparent molecular mass of 94 kDa, which was further modified to a 101 kDa form found in the envelope of recombinant virus particles. Penetration kinetics and single-step growth curves indicated that the incorporation of the BVDV E2 glycoprotein in the BHV-1 envelope, which apparently did not require BHV-1-specific signals, interfered with entry into target cells and egress of progeny virions. These results demonstrate that a pestivirus glycoprotein can be expressed efficiently by BHV-1 and incorporated into the viral envelope. BHV-1 thus represents a promising tool for the development of efficacious live and inactivated BHV-1-based vector vaccines.
Introduction
Bovine herpesvirus-1 (BHV-1), a natural pathogen of cattle that causes respiratory and genital diseases and abortions (Gibbs & Rweyemamu, 1977 ; Wyler et al., 1989) , is a member of the subfamily Alphaherpesvirinae, with a genome of approximately 136 kbp (Schwyzer & Ackermann, 1996) . Attenuated live viruses or inactivated virions are used widely as vaccines to control the disease. Recently, vaccines have entered the market that lack the gene encoding glycoprotein E and therefore allow serological differentiation between vaccinated Author for correspondence : Gu$ nther Keil. and wild-type virus-infected cattle (van Oirschot et al., 1996) . There is also growing interest in the development of genetically engineered BHV-1 vaccines with improved efficacy (Ku$ hnle et al., 1996 ; Raggo et al., 1996) and the use of BHV-1 as a vector to vaccinate against BHV-1 and other bovine pathogens (Kit et al., 1991 (Kit et al., a, b, 1992 Ku$ hnle et al., 1998 ; Otsuka & Xuan, 1996 ; Schrijver et al., 1997 ; Taylor et al., 1998) .
We have recently reported expression by BHV-1 of the attachment glycoprotein G of bovine respiratory syncytial virus (BRSV), a class II membrane glycoprotein, from a modified, synthetic ORF (Ku$ hnle et al., 1998) . Modification of the ORF was necessary because the nucleotide composition of a genomic RNA-derived cDNA fragment encompassing the BRSV glycoprotein G ORF was incompatible with expression of stable transcripts within the nucleus of recombinant BHV-1-infected cells. Analysis of the recombinants demonstrated that the BRSV glycoprotein G was incorporated into the envelope of virions and did not interfere significantly with the infectivity of BHV-1. Experiments with calves have proven subsequently that BRSV glycoprotein G-expressing BHV-1 protects efficiently against BRSV and BHV-1 challenge (Schrijver et al., 1997 ; Taylor et al., 1998) .
Here, we describe the construction of a synthetic ORF (E2 syn ORF) that encodes the E2 glycoprotein of bovine viral diarrhoea virus (BVDV), an economically important pathogen of cattle. We demonstrate that the E2 syn ORF is expressed by recombinant BHV-1 and show that this pestivirus class I membrane glycoprotein is associated with the envelope of recombinant BHV-1 virus particles as a disulphide-linked dimer, a form which is present in BVDV-infected cells and BVDV virions (Weiland et al., 1990) .
Methods
Cell culture and viruses. BHV-1 strain Scho$ nbo$ ken (BHV-1\Scho$ ) was obtained from O. C. Straub (Tu$ bingen, Germany) and propagated on Madin-Darby bovine kidney cell clone Bu100 (MDBK-Bu100 ; kindly provided by W. Lawrence and L. Bello, Philadelphia, USA). Cells were grown in Dulbecco's minimum essential medium supplemented with 5 % foetal calf serum, 100 U\ml penicillin, 100 µg\ml streptomycin and 0n35 mg\ml -glutamine. The gD-negative mutant BHV-1\80-221 was propagated on the cell line BU-Dorf, which constitutively expresses BHV-1 glycoprotein D (gD), as described previously (Schro$ der et al., 1997) .
Sequencing of the BVDV strain C86 E2 ORF. Whole-cell RNA was isolated from cells infected with BVDV strain C86, which is a component of the Intervet Bovilis BVD-MD vaccine (kindly provided by Intervet International, Boxmeer, Netherlands), by using the Pharmacia RNA extraction kit as recommended by the supplier. Reverse transcription and PCR amplification of the E2 ORF were done as described previously (Becher et al., 1997) by using primers O1 35A (5h AARTARTCTGTGACATAACT, antisense) and O1 W2 (5h CGCGGA-TCCTGGTGGCCTTATGA, sense). PCR fragments were purified after agarose gel electrophoresis and cloned by using the TA cloning kit (Invitrogen) following the supplier's instructions. Nucleotide sequences of both strands from three independent clones were determined by cycle sequencing with the Thermo Sequenase kit (Amersham).
Construction and cloning of the BVDV E2 syn ORF. Synthetic oligonucleotides (Gibco-BRL) were hybridized as described previously (Ku$ hnle et al., 1998) to generate the double-stranded DNA fragments shown in Table 1 . Cloning was performed by established methods (Sambrook et al., 1989) .
Fragment 1 was ligated via its cohesive ends into BglII\XhoI-cut pSP73, resulting in plasmid pNH1, which was in turn cleaved with StuI and XhoI to receive fragment 2. The resulting plasmid, pNH2, was cleaved with PstI and XhoI and ligated with fragment 3 to obtain pNH3. pNH3 was cleaved with HindIII and XhoI and ligated with fragment 4 to give pNH4. pNH4 was cleaved with SfuI and XhoI and received fragment 5, resulting in pNH5, which was in turn cleaved with Bsu36I and XhoI and ligated with fragment 6. The resulting plasmid, pNH6, was cleaved with EagI and XhoI and ligated with fragment 7 to give plasmid pNH7.
For the integration of fragments A to F, pSP73 was cleaved with BglII and XhoI. Fragment A was ligated into this DNA, resulting in plasmid pCA, which was in turn cleaved with BglII and BstXI and ligated with fragment B. The resulting plasmid, pCB, was cleaved with BglI and SacII and fragment C was integrated to give pCC, which was in turn cleaved with BglII and ApaI and ligated with fragment D to give pCD. pCD was cleaved with BglII and BsrGI and ligated with fragment E, resulting in pCE. pCE was cleaved with BglII and AccI and ligated with fragment F to obtain plasmid pCF.
Finally, plasmid pNH7 was cleaved with BamHI and XhoI and ligated with the purified BamHI-XhoI insert from plasmid pCF to yield plasmid pspE2 syn , containing the reconstructed BVDV E2 ORF. The construction was verified by sequencing after each cloning step.
Construction of other plasmids. To provide a start codon for initiation of translation and a signal peptide for transport and processing of the BVDV E2 glycoprotein, a BamHI-KpnI DNA fragment GAT-CCACCATGGCCCTGTTGGCTTGGGCGGTGATAACAATCTTG-CTGTACCAGCCTGTAGCAGGGTAC (start codon in bold), encompassing the codons for the pestivirus E rns signal sequence (Sig ; MetAlaLeuLeuAlaTrpAlaValIleThrIleLeuLeuTyrGlnProValAlaGlyTyr ; Ru$ menapf et al., 1993) was cleaved from plasmid pgsCP7LE2 (P. Becher & H.-J. Thiel, unpublished) with BglII and KpnI. The isolated fragment was ligated into the BglII\KpnI-cut plasmid pROMe (Ku$ hnle et al., 1996) to give plasmid pROMeSig. Plasmid pROMeSig was cut with KpnI and NotI and ligated with the BVDV E2 syn ORF, which had been cleaved from plasmid pspE2syn with KpnI and NotI. The resulting plasmid was named pROMeSigE2 syn and contained the reconstructed BVDV E2 syn ORF preceded by the pestivirus signal peptide-coding sequence.
In order to test the influence of an intron on the level of expression of the SigE2 syn gene in recombinant BHV-1-infected cells, the chimeric intron sequence contained within a 207 bp AflII fragment of plasmid pCIneo (Promega) was integrated 8 bp upstream from the SigE2 syn ORF into AflII-cleaved pROMeSigE2 syn . This insertion position is 127 nt downstream of the 5h cap site of the MCMV e1 promoter. The correct orientation of the intron sequence within the resulting plasmid pROMeSigE2 syn -intron was verified by sequencing.
For in vitro transcription and translation, the SigE2 syn ORF was isolated from plasmid pROMeSigE2 syn by cleavage with AflII and XhoI, made blunt-ended with Klenow polymerase and integrated into SmaIcleaved pSP73. In the resulting plasmid, pspSigE2 syn , in vitro transcription of the SigE2 syn ORF is under the control of the phage T7 promoter.
Construction of recombinants BHV-1/SigE2 syn and BHV-1/SigE2 syn -intron. In order to integrate the E2 syn ORF into the genome of BHV-1, recombination plasmids pROMeSigE2 syn and pROMeSigE2 syn -intron were co-transfected into MDBK cells with purified BHV-1\80-221 DNA. After complete lysis of the transfected cultures, progeny virus was titrated on MDBK cells. In BHV-1\80-221, the ORF encoding the essential gD is replaced by a lacZ expression cassette (Fig. 2) and, therefore, only viruses that have acquired the gD ORF from the recombination plasmids should be able to replicate productively on non-complementing cells (Fehler et al., 1992 ; Ku$ hnle et al., 1996) . Virions from plaques that did not stain blue under a Bluo-Galcontaining agarose overlay (Fehler et al., 1992) were plaque-purified and the recombinants BHV-1\SigE2 syn and BHV-1\SigE2 syn -intron were selected for further characterization. To verify integration of the expression cassettes into the genomes of the respective viruses, wholecell DNA from MDBK cells infected with BHV-1\SigE2 syn and BHV1\SigE2 syn -intron was prepared 20 h after infection, cleaved with HindIII, transferred to nitrocellulose membranes after electrophoresis in 0n6% agarose gels and hybridized to E2 syn -, BHV-1 gD-, BHV-1 gE-and lacZspecific $#P-labelled DNA fragments. No hybridization was found with the lacZ-specific probe and the sizes of the fragments detected by the other probes were as expected (data not shown). the manufacturer's protocol (Boehringer). In vitro translation of the cRNAs was performed in the presence of 60 µCi [$&S]methionine per reaction mixture in the absence or presence of canine microsomal membranes, as recommended by the supplier (Promega). Labelled proteins were visualized by fluorography after separation on SDS-10 % polyacrylamide gels as described previously (Keil et al., 1985) .
In vitro
RNA isolation, Northern blot hybridization and primerextension analysis. Cytoplasmic RNA was isolated as described previously (Schmitt & Keil, 1996) . Glyoxal-treated RNA (5 µg) was separated in 1 % formaldehyde gels, transferred to nitrocellulose filters and hybridized to $#P-labelled DNA following established procedures (Keil et al., 1987 ; Sambrook et al., 1989) . Primer-extension analysis was performed as described previously (Bu$ hler et al., 1990) . Elongated fragments were separated on 6 % polyacrylamide sequencing gels containing urea and visualized by autoradiography. 5h end-labelled HpaI fragments of pBR322 and 123 bp and 1 kbp ladders (Gibco-BRL) were used as size markers.
Antibodies and sera. BVDV-neutralizing, E2 glycoprotein-specific MAbs 1a16, 1a5, 1c17 and 1D5 (Weiland et al., 1989) were kindly provided by E. Weiland (Tu$ bingen, Germany) and used as mixtures of equal amounts of hybridoma culture supernatants (BVDV E2-specific MAb cocktail). The calf anti-BVDV serum, kindly provided by J. Patel (Intervet UK) was raised by repeated inoculation of BVDV strain C86. The polyclonal serum directed against BHV-1 gD and the gD-specific MAb 21\3\3 have been described elsewhere (Fehler et al., 1992) .
Immunoprecipitation and deglycosylation reactions.
Immunoprecipitation of [$&S]methionine-labelled proteins from infected cells and purified virions was done as reported previously (Keil et al., 1985 ; Fehler et al., 1992) . Immunoprecipitated proteins were visualized by fluorography after separation on SDS-10 % polyacrylamide gels as described previously (Keil et al., 1985) .
For deglycosylation, immunoprecipitated proteins were incubated overnight at 37 mC with 0n4 U N-glycosidase F (Boehringer), 1 mU neuraminidase (Boehringer) or 1 mU neuraminidase and 1n5 mU Oglycosidase (Boehringer) under conditions recommended by the supplier. Single-step growth curves. MDBK-Bu100 cells were infected with BHV-1 at 10 p.f.u. per cell, incubated for 2 min with citrate buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl, pH 3n0) at 2 h postinfection (p.i.), in order to inactivate virions that had not penetrated into the cells, and washed twice with cell culture medium. At the times indicated, supernatants were collected and stored at k70 mC. Cells were washed with PBS, incubated with citrate buffer for 2 min to inactivate cell-associated extracellular virus, washed with PBS and harvested by low-speed centrifugation after trypsinization. Cell pellets were resuspended in 1 ml cell culture medium and stored at k70 mC. Cells and supernatants were thawed and sonicated for 20 s at 80 W in a Branson ultrasonic water-bath. Serial dilutions were titrated on MDBK-Bu100 cells and plaques were counted 3 days later after incubation under semisolid medium containing methyl cellulose.
Penetration kinetics. Penetration kinetics were determined essentially as described previously (Fehler et al., 1992) through low pH inactivation of extracellular virions at different times after a shift of infected cells from 4 to 37 mC. The plaque count of untreated control cultures was defined as 100 % penetration.
Results and Discussion
Integration of the BVDV-E2 syn ORF into the genome of BHV-1/80-221
Attempts to express cDNA-encoded glycoproteins F and G of BRSV, which replicates in the cytoplasm of infected cells, et al., 1986 ; Mayfield et al., 1983) . The wild-type HindIII L fragment is enlarged and the location and direction of transcription of genes encoding the protein kinase (PK) and glycoproteins G (gG), D (gD), I (gI) and E (gE) are indicated by arrows Leung-Tack et al., 1994 ; Takashima et al., 1999 ; Tikoo et al., 1990 ; Whitbeck et al., 1996) . The comparable HindIII fragment of the gD − lacZ + mutant BHV-1/80-221 is depicted below. The location and direction of transcription of the lacZ cassette (dotted area, not to scale) that replaces the gD ORF is indicated. Underneath, a diagram of the integration fragment contained in the recombination vectors is shown. The gD promoter and gD poly(A) segments indicate BHV-1 sequences that provide homologous regions for recombination. In this study, transcription of the SigE2 syn or SigE2 syn -intron ORF (location of the intron is marked by an arrow) was directed by the MCMV e1 promoter (Bu$ hler et al., 1990 ) and polyadenylation of transcripts was mediated by the gD poly(A) signal. Transcription of the BHV-1 gD ORF, which is followed by the MCMV ie2 poly(A) signal (Messerle et al., 1991) , was under the control of the authentic gD promoter.
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by BHV-1 via the nucleus were not successful. Modification of the BRSV glycoprotein G ORF was necessary for transcription of stable mRNA in recombinant BHV-1-infected cells. It was assumed that splice signals or as yet unidentified sequence motifs resulted in the degradation of nuclear transcripts from the respective cDNA ORFs (Ku$ hnle et al., 1998) .
Analysis of the cDNA sequence encoding the E2 glycoprotein of BVDV strain C86 revealed the presence of motifs identical or similar to splice-donor consensus sequences (Mount, 1982) at positions 152-157, 419-424, 614-619 and 1061-1066 and a consensus sequence for polyadenylation (Birnstiel et al., 1985 ; McLauchlan et al., 1985) at positions 913-918 (Fig. 1) . Since it has been shown that the presence of a splice-donor consensus sequence within a pestivirus E2 glycoprotein-encoding cDNA led to splicing of transcripts after synthesis in the nucleus (Shiu et al., 1997) , we constructed a modified ORF encoding the BVDV strain C86 E2 glycoprotein (E2 syn ORF) for expression by BHV-1. If compatible with the cloning strategy, the codon usage of the E2 syn ORF was adapted to that of BHV-1 gD and the above-mentioned splice-donor and polyadenylation consensus sequences were altered. It should be noted that, in this study, instability or splicing of transcripts from a genomic RNA-derived cDNA fragment has not been analysed. In a previous report, cDNA that encompassed the ORF encoding the classical swine fever virus (CSFV) E2 glycoprotein was integrated into the genome of pseudorabies virus (van Zijl et al., 1991) . The resulting recombinants expressed the CSFV E2 glycoprotein in cell culture and pigs vaccinated with infectious virions were protected against disease caused by both pseudorabies virus and CSFV. The CSVF E2 ORF used in that study did not contain splice-donor consensus sequences, and therefore could result in nuclear transcripts that were not processed by splicing.
In order to allow proper intracellular transport and processing of the E2 glycoprotein, the sequence encoding the signal peptide preceding the pestivirus glycoprotein E rns (Sig) was fused in-frame to the 5h end of the E2 syn ORF (see Methods). To test whether RNA encompassing the resulting SigE2 syn ORF within plasmid pspSigE2 syn had the potential to direct synthesis of a glycoprotein, mRNA was transcribed in vitro and translated in a cell-free rabbit reticulocyte lysate with or without canine microsomal membranes. Translation products were analysed by SDS-10 % PAGE under reducing (see Fig. 5 a) and non-reducing conditions (not shown). The apparent molecular mass of 43 kDa for the protein synthesized in the absence of membranes was in agreement with the calculated size of 44n7 kDa. In the presence of canine microsomal membranes, the in vitro translation products migrated at 54 kDa, indicating that the primary translation product encoded by the E2 syn ORF was translocated and modified by addition of N-linked carbohydrates. Electrophoresis of the in vitro-translated polypeptides under nonreducing conditions revealed the same migration behaviour as after reduction, indicating that in vitro synthesis did not result in dimerization, even after translocation and core glycosylation.
Attempts to immunoprecipitate the in vitro translation products by using a calf serum against BVDV strain C86 or a cocktail containing BVDV E2-specific MAbs (Weiland et al., 1989) were not successful (see Fig. 5 a) .
Transcription from SigE2 syn and SigE2 syn -intron genes in recombinant BHV-1-infected cells
In order to test for transcripts containing the recombinant BVDV E2 ORFs, cytoplasmic RNA isolated at 6 h p.i. from cells infected with BHV-1\SigE2 syn (Fig. 3, lanes 1) or BHV1\SigE2 syn -intron (Fig. 3, lanes 2 ) was analysed by Northern blot hybridization. The probe representing the BVDV E2 ORF hybridized to RNAs of 1n8 and 1n9 kb after infection with BHV-1\SigE2 syn and BHV-1\SigE2 syn -intron, respectively (Fig. 3 a, lanes 1 and 2) . A BHV-1 gD-specific probe detected transcripts of 1n8 kb in both BHV-1\SigE2 syn -and BHV1\SigE2 syn -intron-infected cells (Fig. 3 a, lanes 3 and 4) . Taking into account the increase in size of mRNAs resulting from CIED J. Schmitt and others J. Schmitt and others (Fig. 1) was hybridized to 5 µg RNA and extended by reverse transcription in the presence of [α- 32 P]dCTP. Extension products were separated on a 6 % acrylamide sequencing gel and visualized by autoradiography. Fragment sizes are indicated in nucleotides.
polyadenylation, the lengths of the RNAs were as expected.
Comparison of the intensities of the signals between the SigE2 syn and SigE2 syn -intron RNAs and the signals obtained with the corresponding gD transcripts as internal standards indicated that the presence of the intron within the SigE2 synintron gene might have increased the steady-state level of the transcripts slightly. However, any effect was apparently less significant than the effects observed in other systems (Petitclerc et al., 1995) .
In order to demonstrate that the transcripts originating from the SigE2 syn -intron gene represented spliced RNAs, an oligonucleotide complementary to positions 103-144 (Fig. 1) was hybridized to the RNA and elongated by reverse transcriptase. Extended DNA fragments of 339 and 409 nt, respectively, were detected with RNA from BHV-1\SigE2 synand BHV-1\SigE2 syn -intron-infected cells (Fig. 3 b, lanes 1 and  2) . No specific extension product was found when RNA from non-infected cells was used (Fig. 3 b, lane 3) . Provided that initiation of transcription downstream from the MCMV e1 promoter occurs at the same position in murine MCMVinfected cells (Bu$ hler et al., 1990) and bovine recombinant BHV-1-infected cells, the expected sizes of the elongated transcripts were 343 nt for BHV-1\SigE2 syn , 413 nt for spliced BHV-1\SigE2 syn -intron RNA and 546 nt for unspliced BHV1\SigE2 syn -intron transcripts. Thus, the chimeric intron sequence was removed from the primary SigE2 syn -intron transcripts, which demonstrates that the splice signals provided by the chimeric intron were recognized. The four nucleotide difference between the expected and determined sizes of the extended molecules is probably due to compressions during electrophoresis. It is also possible that alternative 5h cap sites for the MCMV e1 promoter directed transcription within the BHV-1 genome. 4 and 7) , BHV-1/SigE2 syn (2, 5 and 8) and BHV-1/SigE2 syn -intron (3, 6 and 9). Culture medium containing 35 S-labelled methionine and cysteine was added at 2 h p.i. and replaced with normal medium at 10 h p.i. and cells were harvested 2 h later. Lysed cells were incubated with the polyclonal calf anti-BVDV serum (lanes 1-6) or BHV-1 gD-specific MAb 21/3/3 (lanes 7-9). Immunoprecipitated proteins were separated on SDS-10 % polyacrylamide gels under reducing (lanes 1-3) or non-reducing conditions (lanes 4-9). (b) 35 S-labelled proteins from cells infected for 10 h with BHV-1/SigE2 syn (lanes 1 and 2) and wild-type BHV-1 (3) or from purified BHV-1/SigE2 syn (4, 5, 7 and 8) and wild-type BHV-1 (6 and 9) were immunoprecipitated with the polyclonal calf anti-BVDV serum (lanes 1, 4 and 7), the BVDV E2-specific MAb cocktail (2, 5 and 8) or BHV-1 gD-specific MAb 21/3/3 (3, 6 and 9). Bound proteins were separated on SDS-10 % polyacrylamide gels under reducing (lanes 1-6) or non-reducing conditions (7-9).
Identification and characterization of the BVDV E2 glycoprotein expressed by BHV-1
In order to identify the BVDV SigE2 syn ORF-encoded polypeptide, metabolically $&S-labelled proteins from cells infected with BHV-1\SigE2 syn , BHV-1\SigE2 syn -intron and wild-type BHV-1 were immunoprecipitated by using the calf polyclonal anti-BVDV serum or BHV-1 gD-specific MAb 21\3\3 (Fig. 4 a) . Comparable amounts of a protein that migrated in SDS-polyacrylamide gels with an apparent molecular mass of 54 kDa under reducing conditions and 94 kDa under non-reducing conditions were precipitated specifically from BHV-1\SigE2 syn -and BHV-1\SigE2 synintron-infected cells (Fig. 4 a ; lanes 2, 3, 5 and 6 ). These proteins were not precipitated from wild-type BHV-1-infected cells. BHV-1 gD, which migrates with an apparent molecular mass of 72 kDa under both reducing (not shown) and nonreducing conditions, was precipitated by MAb 21\3\3 from all cell lysates (Fig. 4 a, lanes 7-9) . The similar intensities of the bands generated by gD demonstrated that the cells were 35 S]cysteine for 30 min at 6 h p.i. Thereafter, cells were washed with normal cell culture medium and further incubated for 0 (lanes 1 and 7), 15 (2 and 8), 30 (3 and 9), 60 (4 and 10), 90 (5 and 11) and 120 min (6 and 12). Proteins were immunoprecipitated with the calf polyclonal anti-BVDV serum (lanes 1-6) or a rabbit polyclonal serum raised against purified BHV-1 gD (7-12). Lanes 1-3 and 4-6 were run on the same gels ; exposure times were 4 days and 4 weeks, respectively. comparably infected. We conclude from these results that, in infected cells, the BHV-1-expressed BVDV E2 glycoprotein exhibited an apparent molecular mass of 54 kDa and formed a 94 kDa homodimer. This is in good agreement with the migration behaviour of the monomeric and homodimeric forms of the E2 glycoprotein found in BVDV-infected cells (Weiland et al., 1990) . In addition, the results show that the presence of the intron in BHV-1\SigE2 syn -intron does not improve expression of the E2 glycoprotein significantly.
CIEE
In order to investigate whether the E2 glycoprotein was associated with recombinant BHV-1 particles, proteins from purified, $&S-labelled BHV-1\SigE2 syn virions were precipitated by the calf anti-BVDV serum, the BVDV E2-specific MAb cocktail and gD-specific MAb 21\3\3. Immunoprecipitations of infected-cell proteins, labelled with $&S under conditions that allow detection of the 63 kDa gD-precursor molecule (Fig. 4 b, lane 3) , which is not incorporated into virions, were performed to control the purity of the virus preparation (Fig. 4 b, lanes 6 and 9) . Interestingly, the glycoprotein E2 monomer and the dimeric form precipitated from virions by the calf serum and the MAb cocktail migrated slightly more slowly in SDS-polyacrylamide gels (Fig. 4 b, lanes 4, 5, 7 and 8) than the corresponding proteins from infected cells (Fig. 4 b, lanes 1 and 2 ; data for non-reducing conditions not shown) and exhibited apparent molecular masses of 57 and 101 kDa, respectively. In lane 8 of Fig. 4 (b) , diffuse bands are also visible at positions slightly below that of the glycoprotein E2 monomer. Although they were not analysed further, it is assumed that this signal was created by breakdown products of the dimeric form and did not represent an intact monomer. In conclusion, the E2 glycoprotein is associated with BHV-1\SigE2 syn virions as a dimer, where it exhibits a higher apparent molecular mass than that found for the E2 glycoprotein in infected cells. We assume that the modification(s) leading to the decreased mobility is linked to the release of the recombinant BHV-1 virions.
Cell-free translation of in vitro-transcribed SigE2 syn mRNA without (Fig. 5 a, lane 1) or with (Fig. 5 a, lane 2) canine pancreatic microsomal membranes indicated that the E2 glycoprotein contained N-linked carbohydrates. After synthesis in the presence of microsomal membranes, the protein with an apparent molecular mass of 54 kDa migrated in a comparable manner to the E2 glycoprotein monomer expressed in BHV-1\SigE2 syn -infected cells. However, attempts to immunoprecipitate the in vitro-synthesis products with the calf anti-BVDV serum or the anti-E2 MAb cocktail were not successful (Fig. 5 a, lanes 3-6) , suggesting that intracellular transport and\or dimerization of the E2 glycoprotein is crucial for proper processing. This interpretation was supported by pulse-chase experiments with BHV1\SigE2 syn -infected cells (Fig. 5 c) . In contrast to BHV-1 gD, for which conversion of the 63 kDa precursor molecules to the mature 72 kDa glycoprotein could be observed (Fig. 5 c, lanes  7-12) , only increasing amounts of the presumably mature intracellular 54 kDa glycoprotein E2 form were detected by the calf anti-BVDV serum during the chase period (Fig. 5 c,  lanes 1-6) . Only the 94 kDa intracellular homodimer appeared after electrophoresis under non-reducing conditions (not shown). Conversion to the 57 or 101 kDa forms found in virions was not observed. The same result was obtained with the anti-E2 MAb cocktail. The observation that the calf anti-BVDV serum and the anti-E2 MAb cocktail did not react with the in vitro-synthesized, core-glycosylated E2 protein and the failure of these antibodies to precipitate E2 glycoprotein precursor molecules in pulse-chase experiments are in accordance with the conclusion that intracellular transport is required for proper folding and\or modification of the BHV-1-expressed E2 glycoprotein. Longer exposure of the gel shown in Fig. 5 (c) gave no indication of intracellular formation of the 57 kDa glycoprotein E2 form found in BHV-1\SigE2 syn virions, supporting the assumption that this modification is connected with the release of recombinant BHV-1 virus particles.
The carbohydrate composition of the E2 glycoprotein was analysed by incubation of immunoprecipitated E2 with N- Fig. 6 . Delayed penetration of BHV-1/SigE2 syn virions into cells. Stocks of wild-type BHV-1 () and BHV-1/SigE2 syn ($) were diluted to yield approximately 300 p.f.u./ml and penetration kinetics were determined as described previously (Fehler et al., 1992) , by using low-pH inactivation of extracellular virus at different times after a shift of infected cells from 4 to 37 mC to allow membrane fusion. Results shown represent a typical experiment.
glycosidase F and neuraminidase together with O-glycosidase. The electrophoretic mobility of the 54 kDa E2 glycoprotein (Fig. 5 b, lane 1) appeared to be unaffected after incubation with neuraminidase together with O-glycosidase (Fig. 5 b, lane 3) . Digestion with N-glycosidase F resulted in a reduction of the apparent molecular mass to 43 kDa, a size comparable to that of the in vitro-translation product shown in Fig. 5 (a) , lane 1. However, since the BHV-1-expressed E2 glycoprotein probably lacks the signal peptide, the removal of the N-glycans should have resulted in an apparent molecular mass of about 40 kDa. Whether this discrepancy is due to additional modifications, the presence of O-glycosidase-resistant O-linked carbohydrates (Kurilla et al., 1995) , dimerization or folding after synthesis in infected cells needs to be analysed. The origin of the distinct bands migrating above and below the E2 glycoprotein in each lane in Fig. 5 (b) is not clear. They may represent breakdown products of high molecular mass proteins that bind non-specifically to the Staphylococcus aureus cells used for immunoprecipitation .
Effect of E2 expression on entry and release of BHV-1
The penetration behaviour of BHV-1\SigE2 syn was analysed to test whether the presence of the E2 glycoprotein influenced the entry of virions into the target cells. Fig. 6 shows the result of a representative experiment. About 50 % of infectious wild-type BHV-1 particles were protected from low pH-mediated inactivation after about 15 min, whereas entry of BHV-1\SigE2 syn virions required 60 min for 50 % penetration and more than 2 h to enter the cells completely. Thus, association of the E2 glycoprotein with BHV-1 hindered the penetration process significantly, an effect that was not seen with recombinant virions containing BRSV glycoprotein G (Ku$ hnle et al., 1998) .
Replication and release of BHV-1\SigE2 syn and wild-type BHV-1 in MDBK-Bu100 cells is illustrated in Fig. 7 , which shows single-step growth curves from a representative experiment. The generation of intra-and extracellular infectivity in BHV-1\SigE2 syn -infected cells was different to that found for wild-type BHV-1. In BHV-1\SigE2 syn -infected cells, release of virions appears to have been impaired, since infectivity in the supernatants only surpassed that found in infected cells after about 32 h, whereas a similar ratio was attained by wild-type BHV-1 before 20 h p.i. This result may indicate interference of the E2 glycoprotein with the egress of BHV-1. However, we have always observed a delay in release of recombinant BHV-1 virions that express a heterologous glycoprotein (Ku$ hnle et al., 1996 (Ku$ hnle et al., , 1998 G. M. Keil, unpublished results) . The delay might therefore be related to the incorporation of de novo-synthesized glycoproteins into the cellular compartments involved in BHV-1 glycoprotein processing and viral envelope formation.
In conclusion, our results demonstrate that BHV-1 is a suitable vector for expression of the BVDV E2 membrane glycoprotein in a conformation that is at least similar to that of BVDV-expressed E2. They show that incorporation of the E2 glycoprotein into BHV-1 particles does not require herpesvirus-specific signal sequences. With regard to vector vaccine development, the presence of the E2 glycoprotein in recombinant BHV-1 virions raises the possibility of using BHV-1 expressing BVDV E2 as a live or inactivated vaccine.
